Moxifloxacin ameliorates clinical disease activity and histopathological changes of acetic acid-induced colitis model in rat possibly through its effect on proinflammatory mediators and oxidative stress

Abstract

Background: Moxifloxacin (MFX), a fluoroquinolone antibiotic, was found in previous study to exert an anti-inflammatory effect including reduction of proinflammatory cytokine expression, the aim of this research was to investigate the potential anti-inflammatory effect of MFX on acetic acid (AA)-induced colitis model in rats.Methods: About 40 males of Wistar rats were divided into four groups as following, the negative (healthy) control group, AA-colitis group, sulfasalazine (SLS)group, and MFX group. Colitis induction was done by intra-rectal injection of 2 ml AA (4% v/v). After two hours of induction, SLS (100 mg/kg/day) and MFX (8 mg/kg/day) were given by oral route for seven consecutive days.Results: The administration of MFX substantially decreased the disease activity index (DAI), and histopathological alterations triggered by AA. Moreover, AA induced a significant rise in the production of the proinflammatory cytokine IL-1β, the adhesion molecules ICAM-1, and the oxidative stress (OS) biomarker myeloperoxidase (MPO) in colon homogenate. the MFX administration significantly reduced the production of proinflammatory cytokine IL-1 β, adhesion molecules ICAM-1, and the OS biomarker myeloperoxidase (MPO) in colon homogenate, which were elevated by AA. The influences of MFX seemed comparable to those of SLS, with no significant difference between them.Conclusion: Consequently, MFX may possess a beneficial property in the treatment of ulcerative colitis (UC).Keywords: Ulcerative; Colitis; Moxifloxacin; Sulfasalazine; ICAM-1; IL-1β; MPO

Topics & Concepts